Roginolisib not checked

iOnctura · IOA-244

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total · 5 in the EU
Targets
 

What this is

How it works
Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
How it’s given
“IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD”In the company’s words, NCT06887803 on ClinicalTrials.gov
Tested for
Uveal Melanoma (2 trials), Ocular Melanoma, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC, Myelofibrosis (MF), Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC and 1 more
Main trialPhase 2
“The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?”In the company’s words, NCT06717126 on ClinicalTrials.gov
Other names
IOA-244

Other drugs for Uveal Melanoma

All 20 drugs for Uveal Melanoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Dec 2027 A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Phase 1/2Active, not recruiting Jan 2027 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
Phase 1/2Recruiting Mar 2028 A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Phase 1Active, not recruiting 13 Dec 2023 A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Phase 1/2Authorised not given PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Roginolisib

Following is part of Solo: you see every change to Roginolisib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in